BioMarin (BMRN)
Develops rare-disease medicines across enzyme therapies, metabolic disorders, and skeletal conditions.
$63.23
After hours−0.14 (−0.22%)
At close$63.37(−1.08%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 581 | 646 | 649 | 712 | 746 | 747 | 745 | 825 | 776 | 875 | 766 | 990 |
| Cost of revenue | 128 | 135 | 125 | 130 | 188 | 136 | 152 | 150 | 140 | 295 | 195 | 203 |
| Gross profit | 453 | 511 | 524 | 582 | 557 | 611 | 594 | 675 | 636 | 579 | 571 | 787 |
| 423 | 497 | 435 | 461 | 443 | 450 | 370 | 398 | 683 | 500 | 442 | 676 | |
| Research & development | 191 | 206 | 205 | 184 | 185 | 174 | 159 | 161 | 409 | 192 | 179 | 207 |
| 173 | 275 | 226 | 263 | 254 | 267 | 206 | 232 | 268 | 802 | 258 | 396 | |
| Selling & marketing | 122 | 133 | 119 | 123 | 109 | 126 | 103 | 122 | 131 | 0 | 125 | 142 |
| General & administrative | 51 | 142 | 107 | 140 | 145 | 141 | 104 | 110 | 137 | 802 | 133 | 253 |
| Other expenses | 59 | 15 | 4 | 14 | 5 | 10 | 5 | 5 | 5 | −494 | 4 | 73 |
| Operating income | 31 | 14 | 88 | 120 | 114 | 161 | 224 | 277 | −47 | 79 | 130 | 111 |
| 11 | 5 | 17 | 12 | 21 | 8 | 14 | 21 | 20 | −107 | 12 | −50 | |
| Interest income | 16 | 18 | 19 | 20 | 18 | 18 | 19 | 19 | 18 | 19 | 23 | 10 |
| Interest expense | 4 | 6 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 15 | 63 |
| Other non-operating income | −15 | −11 | −21 | −15 | −24 | −10 | −17 | −24 | −23 | 104 | −27 | −14 |
| Income before tax | 42 | 19 | 106 | 132 | 134 | 170 | 238 | 298 | −26 | −27 | 141 | 61 |
| Income tax expense | 1 | −1 | 17 | 25 | 28 | 45 | 52 | 57 | 4 | 19 | 36 | 17 |
| Net income from continuing operations | 40 | 20 | 89 | 107 | 106 | 125 | 186 | 241 | −31 | −47 | 106 | 45 |
| Net income | 40 | 20 | 89 | 107 | 106 | 125 | 186 | 241 | −31 | −47 | 106 | 45 |
| EPS, basic | $0.21 | $0.11 | $0.47 | $0.56 | $0.57 | $0.66 | $0.97 | $1.25 | −$0.16 | −$0.24 | $0.55 | $0.23 |
| EPS, diluted | $0.21 | $0.11 | $0.46 | $0.55 | $0.55 | $0.64 | $0.95 | $1.23 | −$0.16 | −$0.22 | $0.54 | $0.23 |
| Weighted average shares, basic | 188 | 188 | 189 | 190 | 190 | 191 | 191 | 191 | 192 | 192 | 192 | 193 |
| Weighted average shares, diluted | 191 | 192 | 199 | 201 | 197 | 197 | 196 | 197 | 192 | 197 | 198 | 194 |
| EBITDA | 71 | 52 | 136 | 162 | 156 | 195 | 263 | 319 | −5 | −4 | 173 | 222 |
| Depreciation & amortization | 26 | 27 | 27 | 26 | 19 | 24 | 22 | 19 | 18 | 20 | 16 | 98 |
| EBIT | 45 | 25 | 109 | 136 | 137 | 172 | 241 | 301 | −24 | −24 | 156 | 125 |